Approval · Notice of Compliance 37676 · 2026
GABAPENTIN: Notice of Compliance 37676
Issued June 8, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37676
- Date
- June 8, 2026
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02568845 | Approved |
| GABAPENTIN | 02568853 | Approved |
| GABAPENTIN | 02568861 | Approved |
| PRO-GABAPENTIN | 02310473 | Marketed |
| PRO-GABAPENTIN | 02310481 | Marketed |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB